Meeting
2020 Genitourinary Cancers Symposium
Acute patient-reported toxicities after proton therapy or intensity-modulated radiotherapy for prostate cancer.
Authors
Kimberly Gergelis
Department of Radiation Oncology, Mayo Clinic, Rochester, MN
Kimberly Gergelis , Miao Bai , Thomas Whitaker , David M. Routman , Mustafa Sir , Richard Choo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 305)
Abstract #
305
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
A treatment planning comparison of proton therapy and intensity-modulated radiotherapy (IMRT) for prostate cancer using the normal tissue complication probability (NTCP).
First Author: Benjamin Walker Fischer-Valuck
Poster
2022 ASCO Genitourinary Cancers Symposium
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.
First Author: David James Carpenter
Poster
2020 Genitourinary Cancers Symposium
Eight-year outcomes of a phase III randomized trial of conventional versus hypofractionated high-dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Update from the CHHiP Trial.
First Author: David P. Dearnaley
Poster
2019 Genitourinary Cancers Symposium
Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction).
First Author: Omar Y. Mian